Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes

Familial Cancer(2024)10.1007/s10689-024-00370-7Source: DataRank Database

Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes is a research paper published in Familial Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.51)OA: hybridTopics (63)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Mark W. Hazel,John C. Schell,Jared Rutter ORCID,Ruoxin Yao,Alyssa P. Mills

Live enrichment

PubMed:38609520 PMC:PMC11512843 OpenAlex:https://openalex.org/W4394742347

Huntsman Cancer Institute, University of Utah

Grant: Colon Disease Oriented Team Grant

Intramural NIH HHS

Grant: Z99 ES999999

NCI NIH HHS

Grant: R01 CA228346

University of Utah

Grant: Academic Excellence Seed Grant

National Institutes of Health

FWCI

1.51

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://link.springer.com/content/pdf/10.1007/s10689-024-00370-7.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s10689-024-00370-7.pdf

journalhttps://doi.org/10.1007/s10689-024-00370-7

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38609520

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11512843

Fields of Study

Genetic factors in colorectal cancerCancer Cells and MetastasisGastric Cancer Management and OutcomesHumansOrganoidsErbB ReceptorsAdenomatous Polyposis ColiErlotinib HydrochlorideSulindacColorectal Neoplasms, Hereditary NonpolyposisColonic PolypsFemaleMiddle AgedColonMaleProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins B-rafMutationAdultProtein Kinase InhibitorsSignal TransductionNeoplastic Syndromes, Hereditary

MeSH Terms

Erlotinib HydrochlorideAdultColonColonic PolypsColorectal Neoplasms, Hereditary NonpolyposisFemaleHumansMaleMiddle AgedMutationNeoplastic Syndromes, HereditaryOrganoidsAdenomatous Polyposis ColiSulindacSignal TransductionProto-Oncogene Proteins p21(ras)Protein Kinase InhibitorsProto-Oncogene Proteins B-rafErbB Receptors

Keywords

Colorectal cancerFamilial adenomatous polyposisKRASSulindacErlotinibOrganoidMedicineAdenomatous polyposis coliWnt signaling pathwayCancer researchCetuximabCancerInternal medicineBiologyEpidermal growth factor receptorGeneGeneticsGene ExpressionLynch SyndromeColon polypSerrated PolyposisColon Organoid

Sustainable Development Goals

SDG 0: Good health and well-being